The content on this site is intended for healthcare professionals only
Prof George Sledge presents data data from the MONARCH 2 trial during a press conference at the 2019 ESMO congress.
The MONARCH 2 trial looked at the CDK4/6 inhibitor abemaciclib plus fulvestrant in pre-, and peri- and postmenopausal breast cancer patients.
Watch Prof Sledge's interview with ecancer here.
Watch Prof Nadia Harbeck's comment here.
Read more about the study here.
ASCO 2026: Breast cancer overview
Post-chemo olaparib continues to improve efficacy in gBRCApv and high-risk, HER2-negative primary breast cancer
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in HR and HER2 positive early BC
Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma
TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia
Abemaciclib and fulvestrant show improved efficacy in HR+, HER2- advanced breast cancer compared to placebo and fulvestrant
Novel CAR-T cell therapy shows promise against calreticulin mutant neoplasms
